Pfizer Inc. (NYSE:PFE) Shares Purchased by Shepherd Financial Partners LLC

Shepherd Financial Partners LLC raised its holdings in Pfizer Inc. (NYSE:PFE) by 3.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,964 shares of the biopharmaceutical company’s stock after buying an additional 617 shares during the period. Shepherd Financial Partners LLC’s holdings in Pfizer were worth $430,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Pfizer by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company’s stock worth $13,756,738,000 after acquiring an additional 2,285,276 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Pfizer by 19.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock valued at $4,124,330,000 after purchasing an additional 25,315,159 shares in the last quarter. Geode Capital Management LLC increased its stake in Pfizer by 2.5% in the fourth quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company’s stock valued at $3,190,131,000 after purchasing an additional 2,923,537 shares during the last quarter. Norges Bank acquired a new stake in Pfizer during the fourth quarter worth approximately $2,328,986,000. Finally, Massachusetts Financial Services Co. MA lifted its position in shares of Pfizer by 7.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock worth $2,029,604,000 after buying an additional 5,350,381 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

PFE has been the topic of a number of recent analyst reports. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. The Goldman Sachs Group reiterated a “neutral” rating and set a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. UBS Group boosted their target price on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a report on Wednesday, April 30th. Finally, Cantor Fitzgerald initiated coverage on Pfizer in a research note on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $29.17.

Pfizer Stock Down 0.5%

PFE opened at $23.88 on Thursday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The business has a 50 day moving average price of $23.17 and a two-hundred day moving average price of $24.92. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. The company has a market cap of $135.74 billion, a PE ratio of 17.30, a P/E/G ratio of 0.87 and a beta of 0.57.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. During the same quarter in the prior year, the business earned $0.82 earnings per share. The company’s quarterly revenue was down 7.8% compared to the same quarter last year. As a group, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 13th. Stockholders of record on Friday, May 9th were paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.20%. The ex-dividend date was Friday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.